Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Fortress Biotech stock

Own Fortress Biotech stock in just a few minutes.

Posted

Fact checked

Fortress Biotech, Inc is a biotechnology business based in the US. Fortress Biotech shares (FBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Fortress Biotech employs 93 staff and has a trailing 12-month revenue of around USD$43.3 million.

How to buy shares in Fortress Biotech

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Fortress Biotech. Find the stock by name or ticker symbol: FBIO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Fortress Biotech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Fortress Biotech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Fortress Biotech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Fortress Biotech share price

Use our graph to track the performance of FBIO stocks over time.

Fortress Biotech shares at a glance

Information last updated 2020-10-20.
52-week range USD$1.04 - USD$4.78
50-day moving average USD$3.9117
200-day moving average USD$3.0151
Wall St. target price USD$9.46
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.119

Buy Fortress Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Fortress Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fortress Biotech financials

Revenue TTM USD$43.3 million
Gross profit TTM USD$26.1 million
Return on assets TTM -25.17%
Return on equity TTM -106.89%
Profit margin -124.63%
Book value $0.702
Market capitalisation USD$240.9 million

TTM: trailing 12 months

Shorting Fortress Biotech shares

There are currently 2.2 million Fortress Biotech shares held short by investors – that's known as Fortress Biotech's "short interest". This figure is 6.9% up from 2.0 million last month.

There are a few different ways that this level of interest in shorting Fortress Biotech shares can be evaluated.

Fortress Biotech's "short interest ratio" (SIR)

Fortress Biotech's "short interest ratio" (SIR) is the quantity of Fortress Biotech shares currently shorted divided by the average quantity of Fortress Biotech shares traded daily (recently around 1.6 million). Fortress Biotech's SIR currently stands at 1.34. In other words for every 100,000 Fortress Biotech shares traded daily on the market, roughly 1340 shares are currently held short.

However Fortress Biotech's short interest can also be evaluated against the total number of Fortress Biotech shares, or, against the total number of tradable Fortress Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fortress Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Fortress Biotech shares in existence, roughly 20 shares are currently held short) or 0.0331% of the tradable shares (for every 100,000 tradable Fortress Biotech shares, roughly 33 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Fortress Biotech.

Find out more about how you can short Fortress Biotech stock.

Fortress Biotech share dividends

We're not expecting Fortress Biotech to pay a dividend over the next 12 months.

Fortress Biotech share price volatility

Over the last 12 months, Fortress Biotech's shares have ranged in value from as little as $1.04 up to $4.78. A popular way to gauge a stock's volatility is its "beta".

FBIO.US volatility(beta: 2.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fortress Biotech's is 2.2041. This would suggest that Fortress Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Fortress Biotech overview

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site